EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access

Evolving trends and outcomes in older patients with acute myeloid leukemia including allogeneic stem cell transplantation

Alexandre Bazinet iD, Hagop Kantarjian iD, Naszrin Arani, Uday Popat, Alex Bataller iD, Koji Sasaki iD, Courtney D DiNardo iD, Naval Daver iD, Musa Yilmaz iD, Hussein A Abbas iD, Nicholas J Short iD, Ghayas Issa iD und 12 weitere

American Journal of Hematology · 2023-09 · 98 (9) · 1383-1393

DOI: 10.1002/ajh.26997 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift American Journal of Hematology, online erschienen am 19.06.2023. Verfasst von Alexandre Bazinet und 23 weiteren Autor:innen. Beteiligte Einrichtung: Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA. Hauptthemen laut MEDLINE: Hematopoietic Stem Cell Transplantation, Leukemia, Myeloid, Acute. Die Arbeit wurde bisher 19-mal zitiert (Crossref) und nennt 43 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Outcomes in older patients with acute myeloid leukemia (AML) have historically been poor. Given advances in low‐intensity therapy (LIT) and stem cell transplantation (SCT), we performed a retrospective single‐center study to evaluate the contemporary outcomes of this population. We reviewed all patients ≥60 years with newly diagnosed AML between 2012 and 2021 and analyzed treatment and SCT‐related trends and outcomes. We identified 1073 patients with a median age of 71 years. Adverse clinical and cytomolecular findings were frequent within this cohort. In total, 16% of patients were treated with intensive chemotherapy, 51% with LIT alone, and 32% with LIT plus venetoclax. The composite complete remission rate with LIT plus venetoclax was 72%, which was higher than with LIT alone (48%, p < .0001) and comparable to intensive chemotherapy (74%, p = .6). The median overall survival (OS) with intensive chemotherapy, LIT, and LIT plus venetoclax was 20.1, 8.9, and 12.1 months, respectively. 18% of patients received SCT. SCT rates were 37%, 10%, and 22% in patients treated with intensive chemotherapy, LIT, and LIT plus venetoclax, respectively. The 2‐year OS, relapse‐free survival (RFS), cumulative incidence (CI) of relapse, and CI of treatment‐related mortality with frontline SCT ( n = 139) were 59%, 52%, 27%, and 22%, respectively. By landmark analysis, patients undergoing frontline SCT had superior OS (median 39.6 vs. 21.4 months, p < .0001) and RFS (30.9 vs. 12.1 months, p < .0001) compared with responding patients who did not. Outcomes in older patients with AML are improving with more effective LIT. Measures should be pursued to increase access to SCT in older patients.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Hematopoietic Stem Cell TransplantationLeukemia, Myeloid, AcuteHumansAgedDisease-Free SurvivalRetrospective StudiesTransplantation, HomologousStem Cell TransplantationAntineoplastic Combined Chemotherapy ProtocolsSulfonamidesBridged Bicyclo Compounds, Heterocyclic

Substanzen

venetoclaxSulfonamidesBridged Bicyclo Compounds, Heterocyclic

Autor:innen und Institutionen

  • Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
  • Department of Medicine, Baylor College of Medicine, Houston, Texas, USA.
  • Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
  • Department of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.

ORCID-Profile: Alexandre Bazinet, Hagop Kantarjian, Alex Bataller, Koji Sasaki, Courtney D DiNardo, Naval Daver, Musa Yilmaz, Hussein A Abbas, Nicholas J Short, Ghayas Issa, Elias Jabbour, Guillermo Garcia-Manero, Gautam Borthakur, Farhad Ravandi, Tapan Kadia

Förderung

  • NCI NIH HHS

Zitieren

APA

Bazinet, A., Kantarjian, H., Arani, N., Popat, U., Bataller, A., Sasaki, K., DiNardo, C. D., Daver, N., Yilmaz, M., Abbas, H. A., Short, N. J., Issa, G., Jabbour, E., Pierce, S. A., Chen, J., Garcia, R., Konopleva, M., Garcia-Manero, G., Alousi, A., …, & Kadia, T. (2023). Evolving trends and outcomes in older patients with acute myeloid leukemia including allogeneic stem cell transplantation. American Journal of Hematology, 98(9), 1383-1393. https://doi.org/10.1002/ajh.26997

Vancouver

Bazinet A, Kantarjian H, Arani N, Popat U, Bataller A, Sasaki K, et al. Evolving trends and outcomes in older patients with acute myeloid leukemia including allogeneic stem cell transplantation. American Journal of Hematology. 2023;98(9):1383-1393. doi:10.1002/ajh.26997

BibTeX
@article{Bazinet2023,
  author = {Bazinet, Alexandre and Kantarjian, Hagop and Arani, Naszrin and Popat, Uday and Bataller, Alex and Sasaki, Koji and DiNardo, Courtney D and Daver, Naval and Yilmaz, Musa and Abbas, Hussein A and Short, Nicholas J and Issa, Ghayas and Jabbour, Elias and Pierce, Sherry A and Chen, Julianne and Garcia, Ricky and Konopleva, Marina and Garcia-Manero, Guillermo and Alousi, Amin and Shpall, Elizabeth J and Champlin, Richard E and Borthakur, Gautam and Ravandi, Farhad and Kadia, Tapan},
  title = {Evolving trends and outcomes in older patients with acute myeloid leukemia including allogeneic stem cell transplantation},
  journal = {American Journal of Hematology},
  year = {2023},
  volume = {98},
  number = {9},
  pages = {1383--1393},
  doi = {10.1002/ajh.26997}
}
Kostenlos starten →